Primary cancer-associated fibroblasts isolated from fresh breast tumor tissue and cryopreserved at early passage. Identity confirmed by FAP, α-SMA and vimentin. For fibrosis, tumor microenvironment and drug-response studies. Research use only.
$2,500
| Tumor type | Breast Invasive Carcinoma |
| Species | Human |
| Tissue source | Tumor tissue |
| Max recommended passages / lifespan | TBD – finite lifespan, not immortalized |
| Post-thaw viability (guaranteed min %) | ≥ 50% (website: 'viability data (50%+ post-thaw)'). Low for a paid vial – what will DRL guarantee? |
| Cells per vial | ≥ 1 × 10^6 cells (website) |
| Freezing medium | TBD – website names CryoStor for organoids; same for cells? |
| Recommended culture medium | TBD |
| Medium kit available? | TBD |
| Storage on arrival | Liquid nitrogen, vapor phase (website) |
| Ships as | Frozen, on dry ice (website) |
| Biosafety level | BSL-2 (website) |
| Donor data provided | Website: 'comprehensive clinical reports', 'clinical metadata intact'. Which fields exactly? |
| Marker panel | FAP, α-SMA, vimentin (DRL list). Website says 'biomarker-authenticated'. Method & pass rule TBD |
| Mycoplasma test | Included – 'mycoplasma-free' (website) |
| Certificate of Analysis (CoA) | Included – template needed |
| Intended use | Research Use Only. Not for use in humans or for diagnostic procedures. |
| Consent covers commercial sale of derived cells? | TBD (website says 'IRB-approved' – consent scope still unknown) |
